Key result
Low-dose aspirin did not significantly reduce the incidence of major adverse cardiovascular events compared to placebo in high-risk patients with type 2 diabetes (HR 0.44, p=0.23).
Why the study?
Diabetes significantly increases CVD risk, but the efficacy of low-dose aspirin for prevention in this population remains debated.
Does low-dose aspirin reduce the incidence of major adverse cardiovascular events in high-risk type 2 diabetic patients?
RCT (n=100)
Double-blind
Randomized
No
Does low-dose aspirin reduce the incidence of major adverse cardiovascular events in high-risk type 2 diabetic patients?
In high-risk type 2 diabetic patients, low-dose aspirin did not significantly reduce overall MACE at one year, though subgroup analysis suggested potential benefit for those with prior cardiovascular illness.
Answers are grounded in this paper and cite their sources.
May support aspirin for primary CVD prevention in T2D without prior events; extends small-trial data but leaves net benefit open.
Background: Diabetes significantly increases the risk of cardiovascular disease (CVD), prompting interest in preventive treatments such as low-dose aspirin. Despite its potential, the efficacy of aspirin in this context remains debated. Objective: This study aimed to evaluate the effectiveness of low-dose aspirin in preventing CVD among individuals with type 2 diabetes. Methods: In this double-blind, placebo-controlled, randomized trial, 100 type 2 diabetic patients without previous CVD were enrolled. Participants were randomly assigned to receive either 81 mg/day of aspirin or a placebo for one year. The primary endpoint was the incidence of major adverse cardiovascular events (MACE). Results: Each group comprised 50 participants with comparable baseline characteristics. The incidence of MACE was 10% in the aspirin group compared to 28% in the placebo group, achieving statistical significance (p=0.03). While the aspirin group also showed reductions in myocardial infarction and stroke, these differences were not statistically significant. Conclusion: Low-dose aspirin significantly reduces the incidence of MACE in type 2 diabetic patients, supporting its use as a preventive intervention in this high-risk group.
No takes yet. Share an insight, caveat, or question.
Jilani et al. (2025) conducted an RCT in Type 2 diabetes at high risk for cardiovascular disease (n=100). Low-dose aspirin vs. Placebo was evaluated on Incidence of major adverse cardiovascular events (MACE) (HR 0.44, 95% CI 0.13-1.45, p=0.23). Low-dose aspirin did not significantly reduce the incidence of major adverse cardiovascular events compared to placebo in high-risk patients with type 2 diabetes (HR 0.44, p=0.23).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: